Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of BIA 5-1058 in Young and Elderly Subjects
NCT04991194Phase 1Terminated
- Sponsor
- BIAL
- Start
- Oct 2015
- Primary completion
- Dec 2016
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of zamicastat in pulmonary arterial hypertension (PAH) (2 arms), sponsored by BIAL. Primary endpoints: Maximum observed plasma concentration up to 4 weeks, Time of occurrence of Cmax up to 4 weeks and 4 more. Started Oct 2015; status: terminated.
02
Drugs
zamicastat
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT04991194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04991194.